Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptors,
progesterone receptors and lacks HER2 overexpression. This absence of critical molecular …

Antibody–drug conjugates (ADCs) are a potential and promising therapy for a wide variety of
cancers, including breast cancer. ADC-based drugs represent a rapidly growing field of …

Triple-negative breast cancer (TNBC) has been clearly recognized as a heterogeneous
tumor with the worst prognosis among the subtypes of breast cancer (BC). The advent and …

This work compared the metabolic profile of a parental MDA-MB-231 cisplatin-sensitive
triple negative breast cancer (TNBC) cell line with that of a derived cisplatin-resistant line, to …

Triple-negative breast cancer (TNBC) is associated with poor prognosis and limited
treatment options due to the lack of important receptors (estrogen receptor [ER] …

Cancer poses a significant global health challenge, contributing to substantial mortality rates
and driving the urgent need for exploration into bioactive compounds with potent anticancer …

Background Triple-negative breast cancer (TNBC) is an aggressive cancer subtype, owing
to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor …

Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer lacking hormone
receptor expression and HER2 gene amplification. TNBC represents a heterogeneous …

Background Triple-negative breast cancer (TNBC) represents the most aggressive subtype
of breast cancer and is frequently resistant to therapy, ultimately resulting in treatment …

Purpose The complex nature of breast cancer demands flexible and adaptable principles
that can account for the diverse characteristics and evolving conditions of each patient …